NASDAQ:PTCT - PTC Therapeutics Stock Price, Forecast & News

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.15. The biopharmaceutical company had revenue of $71.40 million for the quarter, compared to analysts' expectations of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The firm's quarterly revenue was up 33.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.06) earnings per share. View PTC Therapeutics' Earnings History.

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for PTC Therapeutics.

PTC Therapeutics will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PTC Therapeutics issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $306-306 million, compared to the consensus revenue estimate of $302.78 million.

10 equities research analysts have issued 12-month price objectives for PTC Therapeutics' shares. Their forecasts range from $43.00 to $81.00. On average, they expect PTC Therapeutics' stock price to reach $60.50 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.

Media headlines about PTCT stock have been trending very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. PTC Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for PTC Therapeutics.

Some companies that are related to PTC Therapeutics include GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Regulus Therapeutics (RGLS), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (8.88%), State Street Corp (3.80%), Janus Henderson Group PLC (2.41%), Pictet Asset Management Ltd. (1.46%), Geode Capital Management LLC (1.40%) and Candriam Luxembourg S.C.A. (0.98%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

PTCT stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Pictet Asset Management Ltd., Marshall Wace LLP, Prudential Financial Inc., Candriam Luxembourg S.C.A., Asymmetry Capital Management L.P., Sectoral Asset Management Inc and Spark Investment Management LLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

PTCT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Sofinnova Investments Inc., Renaissance Technologies LLC, Janus Henderson Group PLC, Assenagon Asset Management S.A., Eagle Asset Management Inc., Goldman Sachs Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for PTC Therapeutics.

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTCT stock can currently be purchased for approximately $52.85.

PTC Therapeutics has a market capitalization of $3.26 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.View Additional Information About PTC Therapeutics.

The official website for PTC Therapeutics is http://www.ptcbio.com/.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]